Early Breast Protocols

MULTI-029 Olaparib v2
MULTI-033 Capecitabine v1

BRE-026 Paclitaxel albumin bound (Abraxane® Pazenir®) v6

BRE-050 EC-Accelerated Paclitaxel v2

BRE-058 EC for Breast Cancer v2

BRE-059 EC followed by Carboplatin every 3 weeks & weekly Paclitaxel for Breast Cancer v6

BRE-071 Neratinib v2

BRE-075 Trastuzumab emtansine (Kadcyla®) EBC adjuvant v2

BRE-076 Accelerated EC & accelerated paclitaxel v3

BRE-077 Accelerated EC followed by carboplatin (every 3 weeks) with weekly paclitaxel v2

BRE-083 Accelerated EC followed by weekly carboplatin with weekly paclitaxel v1

BRE-089 Abemaciclib and letrozole or alternative endocrine therapy (adjuvant) v2

BRE-092 Neo-adjuvant pembrolizumab in combination with paclitaxel & carboplatin (every 3 weeks) followed by EC and then adjuvant pembrolizumab monotherapy v3

BRE-093 Neo-adjuvant pembrolizumab in combination with paclitaxel & carboplatin (weekly) followed by EC and then adjuvant pembrolizumab monotherapy v3

BRE-096 cNode negative TCPhesgo – trastuzumab (SC) (neo-adjuvant then adjuvant) v1

BRE-097 cNode positive TCPhesgo – Phesgo (neo-adjuvant then adjuvant or adjuvant) v1

BRE-098 cNode negative EC - Phesgo® & paclitaxel (weekly) – trastuzumab SC (neo-adjuvant then adjuvant) v1

BRE-099 cNode positive EC - Phesgo® & paclitaxel (weekly) - Phesgo® (Neo-adjuvant then adjuvant or Adjuvant) v1